Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ardelyx, Inc. manufactures biotechnological drugs. The Company offers pharmaceuticals to correct mineral metabolism imbalance and metabolic disorders by modulating the function of specific transporters, channels, and receptors located on the epithelia of the gastrointestinal tract. Ardelyx serves patients in the United States.
Website: ardelyx.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 77.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 211.1%. On average the margin is decreasing steadily. Gross margin is high, +85.3%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 6.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 683.2% higher than minimum and 59.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -48.7x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $1.4 mln (0.205% of cap.)

Key Financials (Download financials)

Ticker: ARDX
Share price, USD:  (+0.1%)3.995
year average price 5.53  


year start price 7.44 2024-05-23

max close price 7.57 2024-07-01

min close price 3.28 2025-05-14

current price 3.99 2025-05-22
Common stocks: 163 088 367

Dividend Yield:  0.0%
EV / Sales: 66.7x
Margin (EBITDA LTM / Revenue): -1 211.1%
Fundamental value created in LTM:
Market Cap ($m): 650
Net Debt ($m): -50
EV (Enterprise Value): 600
Price to Book: 4.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-12prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX

2025-05-10accessnewswire.com

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Ardelyx, Inc. (ARDX)

2025-05-10accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX

2025-05-09globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX

2025-05-08accessnewswire.com

Ardelyx, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ARDX

2025-05-01seekingalpha.com

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

2025-03-13globenewswire.com

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

2025-03-01seekingalpha.com

Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +

2025-02-24seekingalpha.com

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)

2025-02-20seekingalpha.com

Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-01 2024-05-02 2024-02-22 2023-10-31 2023-08-02 2023-05-03 2023-03-02 2022-11-03
acceptedDate 2024-10-31 16:06:05 2024-08-01 16:05:38 2024-05-02 16:05:25 2024-02-22 16:40:06 2023-10-31 07:03:07 2023-08-02 07:02:50 2023-05-03 16:07:02 2023-03-02 16:05:56 2022-11-03 16:08:35
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 98M 73M 46M 34M 56M 22M 11M 44M 5M
costOfRevenue 16M 10M 8M 5M 7M 3M 2M 3M 732 000
grossProfit 83M 63M 38M 29M 49M 19M 10M 41M 4M
grossProfitRatio 0.84 0.863 0.836 0.852 0.875 0.844 0.865 0.928 0.853
researchAndDevelopmentExpenses 15M 12M 10M 10M 9M 8M 9M 9M 7M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 20M 19M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 65M 65M 53M 48M 33M 27M 27M 20M 19M
otherExpenses 0 2M 2M 2M 1M 2M 1M 375 000 0
operatingExpenses 80M 77M 63M 57M 41M 35M 36M 29M 26M
costAndExpenses 96M 87M 71M 62M 48M 39M 37M 32M 27M
interestIncome 0 0 0 0 2M 0 0 0 0
interestExpense 5M 5M 4M 3M -1M 2M 2M 2M 2M
depreciationAndAmortization 544 000 569 000 435 000 43 812 291 000 642 000 1M 375 000 1M
ebitda 5M -11M -24M -25M 7M -14M -25M 13M -21M
ebitdaratio 0.051 -0.178 -0.527 -0.736 0.131 -0.646 -2.178 0.283 -4.121
operatingIncome 2M -14M -25M -28M 7M -17M -26M 12M -22M
operatingIncomeRatio 0.023 -0.186 -0.536 -0.814 0.131 -0.744 -2.293 0.275 -4.388
totalOtherIncomeExpensesNet -3M -3M -2M 2M -569 000 2M -695 000 -1M -1M
incomeBeforeTax -766 000 -16M -26M -28M 7M -17M -27M 11M -23M
incomeBeforeTaxRatio -0.008 -0.224 -0.574 -0.828 0.121 -0.767 -2.354 0.242 -4.591
incomeTaxExpense 43 000 67 000 121 000 333 000 200 000 4M 14 000 -109 000 1M
netIncome -809 000 -16M -27M -29M 7M -17M -27M 11M -24M
netIncomeRatio -0.008 -0.225 -0.576 -0.838 0.118 -0.767 -2.355 0.242 -4.795
eps -0.003 -0.07 -0.11 -0.12 0.03 -0.08 -0.13 0.06 -0.14
epsdiluted -0.003 -0.07 -0.11 -0.12 0.029 -0.08 -0.13 0.06 -0.14
weightedAverageShsOut 236M 235M 233M 232M 223M 215M 207M 192M 165M
weightedAverageShsOutDil 236M 235M 233M 232M 228M 215M 207M 194M 165M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-01 2024-05-02 2024-02-22 2023-10-31 2023-08-02 2023-05-03 2023-03-02 2022-11-03
acceptedDate 2024-10-31 16:06:05 2024-08-01 16:05:38 2024-05-02 16:05:25 2024-02-22 16:40:06 2023-10-31 07:03:07 2023-08-02 07:02:50 2023-05-03 16:07:02 2023-03-02 16:05:56 2022-11-03 16:08:35
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 47M 42M 36M 21M 34M 30M 92M 96M 62M
shortTermInvestments 143M 144M 166M 163M 131M 98M 38M 28M 29M
cashAndShortTermInvestments 190M 186M 203M 184M 165M 128M 130M 124M 91M
netReceivables 53M 37M 28M 22M 43M 9M 12M 8M 5M
inventory 11M 14M 10M 12M 9M 8M 5M 3M 1M
otherCurrentAssets 29M 26M 17M 8M 7M 5M 6M 5M 23M
totalCurrentAssets 284M 263M 258M 246M 241M 162M 167M 154M 120M
propertyPlantEquipmentNet 5M 5M 6M 7M 8M 8M 9M 11M 11M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 79M 75M 79M 45M 41M 41M 41M 25M 13M
totalNonCurrentAssets 84M 80M 84M 51M 48M 49M 50M 36M 25M
otherAssets 0 1 1 0 0 0 0 0 0
totalAssets 368M 343M 342M 298M 289M 211M 217M 190M 145M
accountPayables 16M 11M 17M 11M 8M 5M 11M 11M 3M
shortTermDebt 5M 7M 4M 4M 4M 31M 31M 31M 30M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 7M 11M 7M 7M 4M 6M 6M 13M 4M
otherCurrentLiabilities 42M 34M 29M 28M 27M 19M 16M 20M 15M
totalCurrentLiabilities 70M 62M 57M 50M 44M 62M 63M 75M 52M
longTermDebt 102M 101M 100M 52M 30M 4M 5M 6M 7M
deferredRevenueNonCurrent 13M 33M 34M 9M 10M 9M 11M 9M 9M
deferredTaxLiabilitiesNonCurrent 0 -22M -34M 0 14M 13M 0 0 0
otherNonCurrentLiabilities 24M 23M 35M 20M 170 000 172 000 12M 2M -12M
totalNonCurrentLiabilities 139M 134M 135M 80M 55M 26M 29M 17M 26M
otherLiabilities 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 4M 5M 778 000 6M 7M 8M 9M 10M 11M
totalLiabilities 210M 196M 191M 131M 98M 88M 92M 92M 78M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 24 000 23 000 23 000 23 000 23 000 22 000 21 000 20 000 19 000
retainedEarnings -890M -889M -873M -846M -817M -824M -807M -780M -791M
accumulatedOtherComprehensiveIncomeLoss 185 000 -101 000 -20 000 224 000 -201 000 -210 000 -20 000 -54 000 -114 000
othertotalStockholdersEquity 1 048M 1 036M 1 024M 1 013M 1 009M 947M 932M 879M 858M
totalStockholdersEquity 158M 147M 151M 167M 191M 123M 125M 98M 67M
totalEquity 158M 147M 151M 167M 191M 123M 125M 98M 67M
totalLiabilitiesAndStockholdersEquity 368M 343M 342M 298M 289M 211M 217M 190M 145M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 368M 343M 342M 298M 289M 211M 217M 190M 145M
totalInvestments 143M 144M 166M 163M 131M 98M 38M 28M 29M
totalDebt 104M 105M 105M 56M 34M 35M 36M 36M 37M
netDebt 57M 63M 69M 35M 670 000 5M -57M -60M -24M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-08-01 2024-05-02 2024-02-22 2023-10-31 2023-08-02 2023-05-03 2023-03-02 2022-11-03
acceptedDate 2024-10-31 16:06:05 2024-08-01 16:05:38 2024-05-02 16:05:25 2024-02-22 16:40:06 2023-10-31 07:03:07 2023-08-02 07:02:50 2023-05-03 16:07:02 2023-03-02 16:05:56 2022-11-03 16:08:35
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -809 000 -16M -27M -29M 7M -17M -27M 11M -23M
depreciationAndAmortization 544 000 569 000 435 000 362 000 291 000 642 000 -3000 109 000 628 000
deferredIncomeTax 0 0 0 499 000 0 -499 000 0 0 0
stockBasedCompensation 9M 11M 8M 4M 3M 3M 3M 2M 2M
changeInWorkingCapital 33M -15M -19M 15M -33M -2M -23M -769 000 -6M
accountsReceivables -16M -9M -6M 21M -34M 3M -4M -3M 415 000
inventory -2M -5M -29M -2M 414 000 -3M -17M -19M -5M
accountsPayables 4M -6M 6M 3M 2M -5M -346 000 8M -1M
otherWorkingCapital 47M 5M 11M -7M -1M 3M -2M 13M -57 000
otherNonCashItems -42M 32M 39M 115 000 910 000 1M 2M 2M 1M
netCashProvidedByOperatingActivities 501 000 -19M -36M -9M -21M -15M -45M 14M -25M
investmentsInPropertyPlantAndEquipment -137 000 -131 000 -150 000 -43 000 -194 000 -93 000 -14 000 -55 000 0
acquisitionsNet 0 0 0 30M 33M 0 0 0 0
purchasesOfInvestments -40M -23M -34M -78M -50M -67M -21M -7M -18M
salesMaturitiesOfInvestments 42M 47M 32M 48M 17M 8M 11M 8M 17M
otherInvestingActivites 0 24M -2M -30M -33M 0 0 0 530 000
netCashUsedForInvestingActivites 2M 24M -3M -30M -33M -59M -10M 1M -832 000
debtRepayment 0 0 -50M -26M 0 0 0 0 0
commonStockIssued 3M 2M 3M 102 000 57M 11M 51M 19M 34M
commonStockRepurchased 0 0 3M 303 000 670 000 0 200 000 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 2M 50M 26M -58M 149 000 0 7000 112 000
netCashUsedProvidedByFinancingActivities 3M 2M 53M 26M 58M 12M 51M 19M 34M
effectOfForexChangesOnCash 0 0 0 -213M 64M 149M 0 0 0
netChangeInCash 6M 6M 15M -12M 4M -62M -4M 35M 8M
cashAtEndOfPeriod 47M 42M 36M 21M 34M 30M 92M 96M 62M
cashAtBeginningOfPeriod 42M 36M 21M 34M 30M 92M 96M 62M 53M
operatingCashFlow 501 000 -19M -36M -9M -21M -15M -45M 14M -25M
capitalExpenditure -137 000 -131 000 -150 000 -43 000 -194 000 -93 000 -14 000 -55 000 0
freeCashFlow 364 000 -20M -36M -9M -22M -15M -45M 14M -25M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-03-02 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 20:02 ET
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-10-28 20:05 ET
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
2024-10-24 20:05 ET
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
2024-10-22 20:05 ET
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
2024-10-21 20:05 ET
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
2024-10-17 12:00 ET
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
2024-10-15 12:00 ET
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
2024-10-09 12:05 ET
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
2024-09-05 12:00 ET
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
2024-08-08 12:00 ET
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
2024-08-01 20:01 ET
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-07-31 12:02 ET
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
2024-07-18 12:00 ET
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
2024-07-17 21:10 ET
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
2024-07-02 19:12 ET
ARDX Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Ardelyx, Inc. for Potential Securities Law Violations
2024-07-02 11:00 ET
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
2024-06-28 12:17 ET
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
2024-05-30 20:02 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-05-22 12:02 ET
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
2024-05-21 12:02 ET
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
2024-05-16 12:01 ET
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
2024-05-14 20:02 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-05-07 12:01 ET
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
2024-05-02 20:02 ET
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-01 12:00 ET
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
2024-04-18 12:00 ET
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
2024-03-28 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-03-25 12:00 ET
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
2024-03-12 20:35 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-02-27 13:00 ET
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
2024-02-22 21:01 ET
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-01 13:00 ET
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
2024-01-12 12:56 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-01-08 13:00 ET
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
2024-01-03 13:03 ET
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
2023-12-20 13:00 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-11-21 21:02 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-11-21 13:01 ET
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
2023-11-15 21:02 ET
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
2023-11-13 21:02 ET
Ardelyx Announces Departure of Board Member
2023-11-10 13:05 ET
Ardelyx to Participate at the Jefferies London Healthcare Conference
2023-11-06 13:00 ET
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
2023-11-03 12:00 ET
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
2023-10-31 11:00 ET
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
2023-10-30 21:42 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-10-23 12:07 ET
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
2023-10-18 20:02 ET
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
2023-10-17 23:23 ET
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
2023-10-17 23:01 ET
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
2023-10-13 12:00 ET
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
2023-10-04 12:00 ET
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
2023-09-28 12:02 ET
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
2023-09-25 08:15 ET
Tenapanor for Hyperphosphatemia Approved in Japan
2023-09-11 12:00 ET
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
2023-09-08 12:00 ET
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-07 12:00 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-08-02 11:00 ET
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
2023-07-27 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-07-26 11:55 ET
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
2023-07-20 20:05 ET
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
2023-07-13 12:00 ET
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
2023-06-29 20:09 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-06-05 12:00 ET
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
2023-05-31 12:00 ET
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
2023-05-23 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-05-17 11:30 ET
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
2023-05-15 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-05-09 12:00 ET
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
2023-05-03 20:02 ET
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
2023-05-01 12:00 ET
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
2023-04-26 12:00 ET
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
2023-04-18 12:00 ET
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
2023-04-13 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-04-12 20:05 ET
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
2023-03-02 21:02 ET
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2023-02-28 13:00 ET
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
2023-02-27 13:15 ET
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
2023-02-23 13:00 ET
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
2023-02-02 21:20 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-12-29 12:00 ET
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
2022-12-23 22:58 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-12-17 00:51 ET
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
2022-11-22 13:00 ET
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
2022-11-16 23:29 ET
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
2022-11-16 14:00 ET
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
2022-11-04 17:39 ET
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
2022-11-03 20:01 ET
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
2022-11-03 14:00 ET
Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on ...
2022-11-02 20:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-10-31 12:00 ET
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
2022-10-27 12:00 ET
Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
2022-10-24 12:00 ET
Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
2022-10-20 20:01 ET
Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
2022-09-30 20:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-09-06 12:00 ET
Ardelyx to Participate in Upcoming Investor Conferences
2022-08-04 20:01 ET
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
2022-08-02 12:00 ET
Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
2022-07-28 12:00 ET
Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
2022-07-01 20:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-06-30 12:00 ET
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
2022-06-21 12:00 ET
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
2022-06-03 12:00 ET
Ardelyx to Present at the Jefferies 2022 Healthcare Conference
2022-05-24 20:01 ET
Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
2022-05-17 20:01 ET
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
2022-05-16 20:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-05-05 20:01 ET
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
2022-04-28 12:00 ET
Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
2022-04-25 11:00 ET
Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
2022-04-12 20:26 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-04-11 11:00 ET
Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
2022-04-07 12:00 ET
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings
2022-04-04 12:00 ET
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
2022-03-09 21:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-03-02 23:55 ET
Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference
2022-02-28 21:01 ET
Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
2022-02-24 13:00 ET
Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners
2022-02-22 13:00 ET
Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
2022-02-04 21:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2021-11-30 12:00 ET
Ardelyx Launching IBSRELA® Second Quarter of 2022
2021-11-12 13:00 ET
Ardelyx Reports Third Quarter 2021 Financial Results
2021-11-11 21:05 ET
Ardelyx to Present at the Jefferies London Healthcare Conference
2021-11-05 12:00 ET
Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021
2021-11-04 12:00 ET
Ardelyx to Pursue Formal Dispute Resolution for Tenapanor
2021-10-29 12:00 ET
Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021
2021-10-13 12:00 ET
Ardelyx Provides Corporate Update Following Type A Meeting with FDA
2021-09-03 12:00 ET
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial
2021-08-13 12:00 ET
Ardelyx Reports Second Quarter 2021 Financial Results
2021-07-29 20:01 ET
Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2021-07-19 20:01 ET
Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2021-06-07 12:00 ET
Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021
2021-05-25 12:00 ET
Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference
2021-05-06 12:00 ET
Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights
2021-04-29 20:15 ET
Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2021-04-16 20:01 ET
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-04-14 12:00 ET
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan
2021-04-12 12:00 ET
Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021
2021-03-30 20:01 ET
Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
2021-03-15 12:00 ET
Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors
2021-03-08 13:00 ET
Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
2021-03-02 00:04 ET
Thérapeutique Knight annonce le lancement commercial canadien de IBSRELA(MC) — un nouveau traitement innovant du syndrome de côlon irritable avec constipation
2021-02-17 13:00 ET
Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2020-11-23 13:00 ET
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-10 13:00 ET
Ardelyx to Present at the Jefferies Virtual London Healthcare Conference
2020-11-06 13:00 ET
Ardelyx to Webcast Virtual Analyst Day
2020-11-05 13:00 ET
Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights
2020-10-22 14:00 ET
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
2020-10-22 12:00 ET
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
2020-10-12 12:00 ET
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
2020-09-15 12:00 ET
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2020-09-08 12:00 ET
Ardelyx to Participate in Three Upcoming Investor Conferences in September
2020-08-06 12:00 ET
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
2020-08-03 12:00 ET
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
2020-06-30 12:00 ET
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2020-06-15 12:00 ET
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
2020-06-10 00:45 ET
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-08 20:01 ET
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
2020-05-26 13:00 ET
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
2020-05-21 21:23 ET
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-18 20:01 ET
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
2020-05-07 20:02 ET
Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
2020-03-16 13:00 ET
Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
2020-03-06 21:02 ET
Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
2020-02-26 13:00 ET
Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
2020-02-19 13:00 ET
Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2019-12-05 04:32 ET
Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
2019-12-04 21:56 ET
Ardelyx Announces Proposed Public Offering of Common Stock
2019-12-03 12:25 ET
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
2019-12-02 21:01 ET
Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
2019-11-26 21:00 ET
Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-25 23:00 ET
Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
2019-11-06 21:05 ET
Ardelyx Announces Presentation at Kidney Week 2019
2019-11-06 21:02 ET
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
2019-10-10 20:00 ET
Ardelyx to Host Analyst Day in New York
2019-09-17 20:01 ET
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
2019-09-03 12:00 ET
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
2019-09-02 20:00 ET
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
2019-08-09 12:00 ET
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
2019-05-30 13:00 ET
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference

SEC forms

Show financial reports only

SEC form 10
2025-05-01 20:04 ET
Ardelyx published news for 2025 q1
SEC form 8
2025-05-01 20:03 ET
Ardelyx reported for 2025 q1
SEC form 8
2025-05-01 20:03 ET
Ardelyx published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Ardelyx published news for 2025 q1
SEC form 10
2025-02-20 12:08 ET
Ardelyx published news for 2024 q4
SEC form 8
2025-02-20 07:34 ET
Ardelyx published news for 2024 q4
SEC form 8
2025-02-20 07:34 ET
Ardelyx reported for 2024 q4
SEC form 10
2025-02-20 00:00 ET
Ardelyx published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Ardelyx published news for 2024 q4
SEC form 10
2024-10-31 16:06 ET
Ardelyx reported for 2024 q3
SEC form 8
2024-10-31 16:04 ET
Ardelyx published news for 2024 q3
SEC form 8
2024-10-31 16:04 ET
Ardelyx reported for 2024 q3
SEC form 10
2024-08-01 16:05 ET
Ardelyx reported for 2024 q2
SEC form 8
2024-08-01 16:03 ET
Ardelyx published news for 2024 q2
SEC form 8
2024-08-01 16:03 ET
Ardelyx reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Ardelyx reported for 2024 q2
SEC form 10
2024-05-02 16:05 ET
Ardelyx published news for 2024 q1
SEC form 8
2024-05-02 16:04 ET
Ardelyx reported for 2024 q1
SEC form 8
2024-05-02 16:04 ET
Ardelyx published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Ardelyx published news for 2024 q1
SEC form 10
2024-02-22 16:40 ET
Ardelyx published news for 2023 q4
SEC form 8
2024-02-22 16:04 ET
Ardelyx reported for 2023 q4
SEC form 8
2024-02-22 16:04 ET
Ardelyx published news for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Ardelyx published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ardelyx published news for 2023 q4
SEC form 10
2023-10-31 07:03 ET
Ardelyx reported for 2023 q3
SEC form 8
2023-10-31 07:02 ET
Ardelyx reported for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Ardelyx reported for 2023 q3
SEC form 10
2023-08-02 07:02 ET
Ardelyx reported for 2023 q2
SEC form 6
2023-08-02 07:01 ET
Ardelyx reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Ardelyx reported for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Ardelyx reported for 2023 q2
SEC form 6
2023-06-20 16:05 ET
Ardelyx published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Ardelyx reported for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Ardelyx reported for 2023 q1
SEC form 6
2023-04-26 16:15 ET
Ardelyx published news for 2023 q1
SEC form 6
2023-04-14 16:17 ET
Ardelyx published news for 2023 q1
SEC form 10
2023-03-02 00:00 ET
Ardelyx reported for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Ardelyx reported for 2022 q4
SEC form 10
2022-11-03 00:00 ET
Ardelyx reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Ardelyx reported for 2022 q3
SEC form 8
2022-08-04 00:00 ET
Ardelyx reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Ardelyx reported for 2022 q2
SEC form 8
2022-05-05 00:00 ET
Ardelyx reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Ardelyx reported for 2022 q1
SEC form 8
2022-02-28 00:00 ET
Ardelyx published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Ardelyx published news for 2021 q4
SEC form 8
2021-11-12 00:00 ET
Ardelyx published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
Ardelyx published news for 2021 q3
SEC form 8
2021-08-13 00:00 ET
Ardelyx published news for 2021 q2
SEC form 10
2021-08-13 00:00 ET
Ardelyx published news for 2021 q2
SEC form 8
2021-07-19 00:00 ET
Ardelyx published news for 2021 q2
SEC form 8
2021-05-06 00:00 ET
Ardelyx published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Ardelyx published news for 2021 q1